Celldex Therapeutics (CLDX) Operating Income (2010 - 2026)

Celldex Therapeutics' Operating Income history runs 17 years deep, the most recent figure standing at -$84.4 million for Q1 2026.

• In Q1 2026, Operating Income fell 34.58% year-over-year to -$84.4 million; the TTM figure through Mar 2026 stood at -$309.1 million (down 42.29% YoY), while the FY2025 annual figure was -$287.4 million, down 47.31% from the prior year.
• Operating Income was -$84.4 million for Q1 2026 at Celldex Therapeutics, up from -$87.2 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of -$23.3 million in Q1 2022 to a low of -$87.2 million in Q4 2025.
• Historically, Operating Income has averaged -$49.2 million across 5 years, with a median of -$46.3 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Operating Income plunged 177.36% in 2022, then grew 8.77% in 2023.
• A 5-year view of Operating Income shows it stood at -$27.9 million in 2022, then slumped by 70.8% to -$47.6 million in 2023, then decreased by 17.64% to -$56.0 million in 2024, then tumbled by 55.56% to -$87.2 million in 2025, then gained by 3.12% to -$84.4 million in 2026.
• The last three Operating Income figures came in at -$84.4 million (Q1 2026), -$87.2 million (Q4 2025), and -$73.6 million (Q3 2025), per Business Quant data.